30 studies found for:    HIV and pre exposure prophylaxis | NIH, U.S. Fed
Show Display Options
Rank Status Study
1 Completed Pre-Exposure Prophylaxis in YMSM
Condition: HIV
Interventions: Drug: coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP;   Drug: Placebo;   Behavioral: Many Men, Many Voices (3MV)
2 Recruiting Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
Condition: HIV Infection
Interventions: Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
3 Recruiting An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)
Condition: HIV Infection
Interventions: Behavioral: 3MV;   Behavioral: PCC;   Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
4 Not yet recruiting Evaluating the Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Healthy, HIV-Uninfected Adolescents
Condition: HIV Infections
Intervention: Drug: Truvada
5 Active, not recruiting The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Condition: HIV Infections
Intervention: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
6 Not yet recruiting Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Rilpivirine;   Drug: Placebo
7 Active, not recruiting An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis
Condition: HIV Infection
Interventions: Behavioral: 3MV;   Behavioral: PCC;   Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
8 Active, not recruiting Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
9 Active, not recruiting Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention
Condition: Clinician Attitudes About PrEP.
Intervention:
10 Completed Behavioral and Biomedical HIV Prevention Interventions for Thai Men Who Have Sex With Men
Condition: HIV Testing, MSM
Intervention:
11 Recruiting Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Behavioral: Sexual Health Counseling;   Behavioral: Enhanced Adherence Intervention;   Behavioral: PrEP Information (Active Control);   Behavioral: Standard of Care Adherence Support (Active Control)
12 Not yet recruiting PrEP for Black Men Who Have Sex With Men (MSM)
Condition: HIV/AIDS
Interventions: Behavioral: Enhanced PrEP Adherence;   Behavioral: Standard PrEP Adherence
13 Completed Determining Characteristics and Behaviors of Adolescent Women Regarding HIV Risk and Microbicide Trial Participation
Condition: HIV Infections
Intervention:
14 Recruiting Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots
Condition: PrEP Adherence Monitoring
Intervention: Drug: Truvada
15 Active, not recruiting Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).
Condition: HIV Infection
Intervention: Drug: FTC/TDF (Truvada®)
16 Completed
Has Results
NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
Condition: HIV Infections
Interventions: Drug: Emtricitabine;   Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine;   Drug: Tenofovir disoproxil fumarate
17 Completed A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN
18 Completed Voluntary HIV Counseling, Testing, and Medication for Pregnant Women to Prevent Mother-to-Child HIV Transmission
Condition: HIV Infections
Interventions: Procedure: Intrapartum HIV counseling/testing;   Procedure: Postpartum HIV counseling/testing
19 Completed A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel;   Drug: Universal HEC Placebo Gel Formulation
20 Completed HIV-1 Resistance at Screening for HIV Prevention Studies
Condition: HIV
Interventions: Procedure: Laboratory Testing;   Other: Counseling/referral

Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results
Indicates status has not been verified in more than two years